Company intelligence / Profile preview
BioGaia AB
Stockholm, Swedenbiogaia.com ↗
- Ownership
- Public · BIOG.B
- Employees
- ~225
- Development stage
- Commercial
01
Overview
BioGaia has conducted more than 260 clinical studies using their human strains of L. reuteri on approximately 22,000 individuals of all ages. Results have been published in more than 250 articles in scientific journals. Their products have shown efficacy in infant colic, diarrhea prevention, H. pylori infection treatment, and gingivitis treatment[6][3].
- Therapeutic areas
- OtherGastroenterologyImmunologyInfectious Diseases
- Modalities
- ProbioticsLive biotherapeutic products
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Financials
- Market cap
- $263
- Total revenue
- $25.9M
- Enterprise value
- $5.4M
Beyond the preview
Go deeper on BioGaia AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioGaia AB.